Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism

Archives of Internal Medicine

Volumn 160, Issue 2, 2000, Pages 229-236

  Hull, Russell D ^a,f   Raskob, Gary E ^b   Brant, Rollin F ^a   Pineo, Graham F ^a   Elliott, Gregory ^c   Stein, Paul D ^d   Gottschalk, Alexander ^e   Valentine, Karen A ^a   Mah, Andrew F ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d HENRY FORD HOSPITAL   (United States)

^e Michigan State University   (United States)

^f FOOTHILLS HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; LUNG EMBOLISM; LUNG SCINTISCANNING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0034707642     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.2.229     Document Type: Article

References (60)

1. Anderson FA Jr, Wheeler B, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep-vein thrombosis and pulmonary embolism: the Worcester Deep-Vein Thrombosis Study. Arch Intern Med. 1991;151:933-938.
2. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158:585-593.
3. Moser KM, LeMoine JR. Is embolic risk conditioned by location of deep venous thrombosis? Ann Intern Med. 1981;94:439-444.
4. Huisman MV, Buller HR, ten Cate JW, et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest. 1989;95: 498-502.
5. Dalen JE, Alpert TS. Natural history of pulmonary embolism. Prog Cardiovasc Dis. 1975;17:257-270.
6. Hull RD, Hirsh J, Carter CJ, et al. Diagnostic efficacy of impedance plethysmography for clinically suspected deep-vein thrombosis: a randomized trial. Ann Intern Med. 1985;102:21-28.
7. Huisman MV, Buller HR, ten Gate JW, Vreeken J. Serial impedance plethysmography for suspected deep venous thrombosis in outpatients: the Amsterdam General Practitioner Study. N Engl J Med. 1986;314:823-828.
8. Hull RD, Hirsh J, Sackett DL, et al. Clinical validity of a negative venogram in patients with clinically suspected venous thrombosis. Circulation. 1981;64:622-625.
9. Dismuke SE, Wagner EH. Pulmonary embolism as a cause of death: the changing mortality in hospitalized patients. JAMA. 1986;255:2039-2042.
10. Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest. 1995;108:978-981.
11. Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg. 1972;104:134-144.
12. Wheeler HB, O'Donnell JA, Anderson FA Jr, Benedict K Jr. Occlusive impedance phlebography: a diagnostic procedure for venous thrombosis and pulmonary embolism. Prog Cardionsc Dis. 1974;17:199-205.
13. Hull RD, Hirsh J, Sackett DL, et al. Combined use of leg scanning and impedance plethysmography in suspected venous thrombosis: an alternative to venography. N Engl J Med. 1977;296:1497-1500.
14. Hull RD, Carter CJ, Jay RM, et al. The diagnosis of acute, recurrent, deep-vein thrombosis: a diagnostic challenge. Circulation. 1983;67:901-906.
15. Dalen JE, Brooks HL, Johnson LW, et al. Pulmonary angiography in acute pulmonary embolism: indications, techniques and results in 367 patients. Am Heart J. 1971;81:175-185.
16. White RH, McGahan JP, Daschback MM, Hartling RP. Diagnosis of deep-vein thrombosis using duplex ultrasound. Ann Intern Med. 1989;111:297-304.
17. Lensing AWA, Prandoni P, Brandjes D, et al. Detection of deep-vein thrombosis by real-time B-mode ultrasonography. N Engl J Med. 1989;320:342-345.
18. Hull RD, Hirsh J, Carter C, et al. Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism. Chest. 1985;88:819-828.
19. Salzman EW, Deykin D, Shapiro RM, Rosenberg R. Management of heparin therapy: controlled prospective trial. N Engl J Med. 1975;292:1046-1050.
20. Glazier RL, Crowell EB. Randomized prospective trial of continuous vs intermittent heparin therapy. JAMA. 1976;236:1365-1367.
21. Mant MJ, O'Brien ED, Thong KL, et al. Haemorrhagic complications of heparin therapy. Lancet. 1977;1:1133-1135.
22. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1986;315:1109-1114.
23. Hull RD, Delmore T, Carter C. et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med. 1982;306:189-194.
24. Hull RD, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982;307:1676-1681.
25. Gallus AS, Jackaman J, Tillett J, et al. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet. 1986;2: 1293-1296.
26. Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med. 1990;322:1260-1264.
27. Hull RD, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med. 1979;301:855-858.
28. Brandjes DPM, Heijboer H, Buller HR, et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1992;327:1485-1489.
29. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. Ann Intern Med. 1993; 119:874-881.
30. Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med. 1992;152:1589-1595.
31. Hull RD, Raskob GE, Brant RF, et al. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy: the emerging theme of delayed recurrence. Arch Intern Med. 1997;157:2317-2321.
32. Hull RD, Raskob GE, Brant RF, et al. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment tor deep vein thrombosis. Arch Intern Med. 1997; 157:2562-2568.
33. Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest. 1998;114(suppl):561S-578S.
34. Salzman EW. Low-molecular-weight heparin: is small beautiful? N Engl J Med. 1986;315:957-959.
35. Verstraete M. Pharmacotherapeutic aspects of unfractionated and low-molecular-weight heparin. Drugs. 1990;40:498-530.
36. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337:688-698.
37. Bergqvist D, Hedner U, Sjorin E, Holmer E. Anticoagulant effects of two types of low-molecular-weight heparin administered subcutaneously. Thromb Res. 1983; 32:381-391.
38. Bara L, Billaud E, Gramond G, et al. Comparative pharmacokinetics of a low-molecular-weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res. 1985;39:631-636.
39. Bratt G, Tornebohm E, Widlund L, Lockner D. Low-molecular-weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res. 1986;42:613-620.
40. Harenberg J, Wurzner B, Zimmermann R, Schettler G, Bioavailability and antagonization of the low-molecular-weight heparin CY 216 in man. Thromb Res. 1986;44:549-554.
41. Frydman AM, Bara L, Le Roux Y, et al. The antithrombotic activity and pharmacokinetics of enoxaparin, a low-molecular-weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol. 1988;28:609-618.
42. Matzsch T, Bergqvist D, Hedner U, Ostergaard P. Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers. Thromb Haemost. 1987;57:97-101.
43. Alach M, Michaud A, Ballan J-L, et al. A new low-molecular-weight heparin derivative: in vitro and in vivo studies. Thromb Res. 1983;31:611-621.
44. Siegbahn A, Y-Hassan S, Boberg J, et al. Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin: a dose finding study with LMWH-Novo. Thromb Res. 1989;55:767-778.
45. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximalvein thrombosis. N Engl J Med. 1992;326:975-982.
46. Prandoni P, Lensing AWA, Buller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet. 1992;339:441-445.
47. Lopaciuk S, Meissner AJ, Filipscki S, et al. Subcutaneous low-molecular-weight heparin versus subcutaneous unfractionated heparin in the treatment of deep-vein thrombosis: a Polish multicentre trial. Thromb Haemost. 1992; 68:14-18.
48. Simonneau G, Charbonnier B, Decousus H, et al. Subcutaneous LMWH compared with continuous intravenous unfractionated heparin in the treatment of proximal deep-vein thrombosis. Arch Intern Med. 1993;153:1541-1546.
49. Lindmarker P, Holmstrom M, Granqvist S, et al. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep-vein thrombosis. Thromb Haemost. 1994;72:186-190.
50. Levine M, Gent M, Hirsh J, et al. A comparison of LMWH administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677-681.
51. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous LMWH administered at home. N Engl J Med. 1996; 334:682-687
52. Columbus Investigators. Low-molecular-weight heparin is an effective and safe treatment of deep-vein thrombosis and pulmonary embolism. Blood. 1996;88: 624-626.
53. PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism: results of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED). JAMA. 1990;263:2753-2759.
54. PISA-PED Investigators. Value of perfusion lung scan in the diagnosis of pulmonary embolism: results of the Prospective Investigative Study of Acute Pulmonary Embolism Diagnosis. Am J Respir Crit Care Med. 1996;154:1387-1393.
55. Stein PD, Terrin ML, Gottschalk A, Alavi A, Henry JW. Value of ventilation/ perfusion scans versus perfusion scans alone in acute pulmonary embolism. Am J Cardiol. 1992;69:1239-1241.
56. Bookstein JJ, Silver TM. The angiographic differential diagnosis of acute pulmonary embolism. Radiology. 1974;110:25-33.
57. Williamson DF, Parker RA, Kendrick JS. The box plot: a simple visual method to interpret data. Ann Intern Med. 1989;110:916-921.
58. ACCP Consensus Committee on Pulmonary Embolism. Second report: opinions regarding the diagnosis and management of venous thromboembolic disease. Chest. 1998;113:499-504.
59. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med. 1992;116:78-84.
60. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin tor acute pulmonary embolism. N Engl J Med. 1997;337:663-669.